IMMvention Therapeutix

Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement with US-headquartered IMMvention Therapeutix, Inc. to develop and commercialize oral therapies targeting the BACH1 pathway for sickle cell disease (SCD) and other chronic conditions. The partnership aims to leverage IMMvention’s expertise in BACH1 inhibition to…